CVS Health (CVS) Aktienübersicht
Die CVS Health Corporation bietet Gesundheitslösungen in den Vereinigten Staaten an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 5/6 |
Belohnungen
Risikoanalyse
Last Earnings Call
Q2 2026 · 5 Aug 2026CVS Health reported strong Q2 2026 results on August 5, 2026, with total revenues of $106.1 billion and adjusted earnings per share (EPS) of $2.58. Both metrics comfortably beat analyst consensus estimates of approximately $100.03 billion in revenue and $1.83–$1.86 in EPS.
Key financial drivers included significant margin recovery within the Health Care Benefits segment, fueled by disciplined medical cost management in its government business, and steady growth across all operating segments. Consequently, management raised its full-year 2026 adjusted EPS guidance to a range of $7.90–$8.10, up from the prior $7.30–$7.50, and increased its operating cash flow outlook to at least $11.5 billion. While providing preliminary 2027 commentary, management signaled a potential $8.44 adjusted EPS floor, noting anticipated membership headwinds in its Caremark PBM business and ongoing pressure in 340B programs.
Market Reaction
Despite initial pre-market gains following the earnings beat and raised guidance, CVS stock fell by approximately 6.5% during regular trading hours on August 5, 2026. Analysts attributed the reversal to management's cautious commentary regarding 2027 headwinds, specifically membership declines in the Caremark segment and 340B-related pressures.
CVS Community Fair Values
Create NarrativeSee what 442 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CVS Health Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$94.91 |
| 52-Wochen-Hoch | US$110.68 |
| 52-Wochen-Tief | US$69.51 |
| Beta | 0.60 |
| 1 Monat Veränderung | -11.69% |
| 3 Monate Veränderung | 1.75% |
| 1 Jahr Veränderung | 33.73% |
| 3 Jahre Veränderung | 41.55% |
| 5 Jahre Veränderung | 13.24% |
| Veränderung seit IPO | 14,356.48% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Aug 10
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold'
Summary CVS Health Corporation's strong Q2 results delivered revenue and earnings beats while management raised operating cash flow guidance to $11.5 billion. Aetna turnaround and improved medical benefit ratios boosted first half cash generation, helping drive recent stock gains. Management anticipates higher second half medical costs alongside 2027 headwinds from 340B pricing and pharmacy drug mix shifts. Strengthening cash flow supports deleveraging and dividend safety, but the recent CVS stock rally keeps the thesis at Hold. Read the full article on Seeking Alpha
Narrative-Update • Aug 05
CVS: GLP 1 Expansion And Legal Risks Will Shape Future Earnings
The analyst price target for CVS Health has shifted from $111.92 to $114.88. This change reflects updated views from recent Street research that focuses on valuation, medical loss ratio trends, regulatory clarity, and ongoing growth investments across its healthcare services businesses.Recent updates
Seeking Alpha • Aug 10
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold'
Summary CVS Health Corporation's strong Q2 results delivered revenue and earnings beats while management raised operating cash flow guidance to $11.5 billion. Aetna turnaround and improved medical benefit ratios boosted first half cash generation, helping drive recent stock gains. Management anticipates higher second half medical costs alongside 2027 headwinds from 340B pricing and pharmacy drug mix shifts. Strengthening cash flow supports deleveraging and dividend safety, but the recent CVS stock rally keeps the thesis at Hold. Read the full article on Seeking AlphaNarrative-Update • Aug 05
CVS: GLP 1 Expansion And Legal Risks Will Shape Future Earnings
The analyst price target for CVS Health has shifted from $111.92 to $114.88. This change reflects updated views from recent Street research that focuses on valuation, medical loss ratio trends, regulatory clarity, and ongoing growth investments across its healthcare services businesses.Narrative-Update • Jul 22
CVS: GLP‑1 Expansion And Legal Settlements Will Shape Future Earnings Stability
The analyst price target for CVS Health has been lifted by about $4 to reflect modestly higher fair value estimates around $112. Analysts point to sector tailwinds in healthcare services, expectations for more stable managed care trends, and company-specific growth investments in areas such as GLP-1 support programs and technology.Narrative-Update • Jul 08
CVS: GLP‑1 Support And Managed Care Stability Will Shape Future Earnings
The analyst price target for CVS Health has been revised higher to $107.73 from $105.38 as analysts factor in modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly higher future P/E multiple, supported by recent sector-wide target increases and company specific developments such as expanded GLP-1 support programs and views of a more stable policy backdrop for managed care. Analyst Commentary Recent research on CVS Health points to a cluster of higher price targets, with analysts focusing on execution in managed care, the impact of GLP-1 support programs, and shifts in policy and utilization assumptions.Narrative-Update • Jun 24
CVS: Medicare Advantage Margins And GLP‑1 Programs Will Shape Future Earnings
Analysts have raised the implied fair value for CVS Health from about $102.85 to roughly $105.38. This change reflects higher Street price targets tied to expanding GLP-1 support programs, a calmer policy backdrop for managed care, and expectations for steadier earnings power across the business.Narrative-Update • Jun 03
CVS: Medicare Advantage Margin Recovery Will Shape Future Earnings Profile
Narrative Update Analysts have nudged the CVS Health fair value estimate from $101.58 to $102.85, reflecting a series of higher price targets in the $106 to $110 range as they highlight margin recovery in government businesses, steadier pharmacy and pharmacy benefit manager earnings after reform, and supportive Q1 medical cost trends. Analyst Commentary Recent Street research on CVS Health clusters around a similar message, with several firms lifting price targets into a tighter band and pointing to company specific factors rather than broad sector calls.Analyseartikel • May 18
Investors Can Find Comfort In CVS Health's (NYSE:CVS) Earnings Quality
CVS Health Corporation's ( NYSE:CVS ) stock was strong despite it releasing a soft earnings report last week. However...Narrative-Update • May 15
CVS: Medicare Advantage Turnaround And PBM Clarity Will Shape Future Earnings Profile
Analysts have lifted the fair value estimate for CVS Health by $5 to $101.58, reflecting a series of higher price targets around $106 that emphasize expectations for a Medicare Advantage turnaround, steadier pharmacy and pharmacy benefit manager earnings, and reduced regulatory uncertainty after recent PBM reform and Federal Trade Commission actions. Analyst Commentary Recent Street research on CVS Health has become more constructive, with a cluster of higher price targets around $106 and several rating upgrades that feed directly into the higher fair value estimate.Analyseartikel • May 08
CVS Health Corporation Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
CVS Health Corporation ( NYSE:CVS ) defied analyst predictions to release its quarterly results, which were ahead of...Narrative-Update • Apr 22
CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Future Earnings
CVS Health's analyst price targets have edged higher by a few dollars, as analysts factor in slightly stronger revenue and margin assumptions, a modestly lower discount rate, and a somewhat lower future P/E multiple in light of recent research that highlights Medicare Advantage exposure, potential earnings stability in pharmacy, and reduced regulatory uncertainty tied to a possible FTC settlement. Analyst Commentary Recent research on CVS Health reflects a mix of cautious optimism and ongoing concern, with analysts adjusting price targets by only a few dollars in either direction as they reassess earnings quality, regulatory risks, and Medicare Advantage exposure.Narrative-Update • Apr 08
CVS: Medicare Advantage Turnaround Will Support Future Earnings Recovery
Analysts have trimmed the average CVS Health price target by a few dollars to around the mid $90s. This reflects slightly softer revenue growth assumptions, modestly higher margin expectations, and updated views on Medicare Advantage and regulatory risks following recent CMS and FTC related commentary.Narrative-Update • Mar 25
CVS: Medicare Advantage Turnaround And FTC Settlement Will Support Earnings Recovery
Analysts have slightly raised their fair value estimate for CVS Health to $96.50, citing improving clarity around potential FTC settlements and a perceived Medicare Advantage turnaround. These developments could support a higher future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.Narrative-Update • Mar 11
CVS: Medicare Advantage Policy And Rates Will Support Future Earnings Recovery
Analysts have adjusted their price targets on CVS Health modestly lower. Our updated fair value estimate has moved from about $94.84 to roughly $96.38 per share.Narrative-Update • Feb 24
CVS: Medicare Advantage And Great Healthcare Plan Will Support Future Margin Recovery
Analysts have trimmed their average price target on CVS Health by a few dollars, citing updated views on Medicare-related policy risks and a slightly lower future P/E assumption, even as they factor in modestly stronger profit margins over time. Analyst Commentary Recent research on CVS Health reflects a mix of optimism around long term earnings potential and caution around policy and reimbursement risk tied to Medicare and broader health reform proposals.Narrative-Update • Feb 09
CVS: Medicare Advantage And Great Healthcare Plan Will Drive Earnings Recovery
Analysts have trimmed their fair value estimate for CVS Health by about $0.20 to $94.76, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and updated sector views after recent price target reductions and commentary around Medicare Advantage and managed care rates. Analyst Commentary Recent Street research around CVS Health centers on Medicare Advantage rate visibility, the outlook for managed care earnings, and shifting expectations for health policy.Narrative-Update • Jan 23
CVS: Medicare Advantage And Great Healthcare Plan Will Support Earnings Rebound
Analysts have nudged their average price targets for CVS Health higher, with increases such as Bernstein moving to $91 from $87, BofA to $100 from $89, and RBC to $93 from $81. These changes reflect views that recent policy developments and Q3 results support a steadier outlook for government managed care earnings and potential catalysts in Medicare Advantage.
Narrative-Update • Jan 09
CVS Health: Rebuilding a Healthcare Giant From the Inside Out
CVS Health (NYSE: CVS) has not been an easy stock to own. Over the past year, investors have watched margins compress, guidance get revised, and sentiment sour as healthcare cost inflation collided with reimbursement pressure.Narrative-Update • Jan 08
CVS: Medicare Advantage Margin Recovery From 2026 Will Drive Earnings Rebound
Narrative Update Analysts have raised their blended price target on CVS Health by about $1, citing recent target increases into the low to mid $90s and $100 range. They also note views that Medicare Advantage and broader managed care earnings could enter recovery phases beginning around 2026, despite expected bumps along the way.Narrative-Update • Dec 23
CVS: Medicare Advantage Margin Recovery Is Expected To Drive Earnings Momentum From 2026
Analysts have modestly raised their price target on CVS Health, with our fair value estimate increasing from approximately $92.44 to $94.33. This reflects growing confidence in earnings visibility, margin recovery in Medicare Advantage, and supportive recent EPS revisions despite mixed near term trends.Narrative-Update • Dec 09
CVS: Medicare Advantage Margin Recovery Will Drive Earnings Momentum From 2026
The analyst price target for CVS Health has edged higher by about $1 to approximately $92, as analysts point to resilient earnings, improving visibility in Medicare Advantage margins, and a solid Q3 performance as support for modestly stronger long term valuation assumptions. Analyst Commentary Research updates highlight a generally constructive view on CVS Health, with multiple firms lifting price targets and emphasizing improved earnings visibility and margin recovery potential over the medium term.Narrative-Update • Nov 25
CVS: Margin Recovery in Medicare Advantage Will Drive Earnings Momentum Through 2026
The analyst price target for CVS Health has been revised slightly lower from $91.52 to $91.48. Analysts point to a mixed quarterly report and evolving expectations around Medicare Advantage and earnings visibility as factors behind the update.Narrative-Update • Nov 08
CVS: Earnings Momentum Will Drive Performance as Regulatory Shifts Unfold
Analysts have raised their fair value estimate for CVS Health to $91.52 from $86.20. This adjustment is due to improved earnings visibility and continued momentum following solid quarterly results.Narrative-Update • Oct 25
Managed Care Margin Recovery And Healthcare Benefits Will Shape Industry Prospects
Analysts have raised their fair value estimate for CVS Health to $86.20. This modest increase is supported by greater earnings visibility and expectations for margin recovery in the managed care sector.Narrative-Update • Oct 10
Digital Health Transformation And Integrated Care Will Expand Reach
Analysts have raised their price target for CVS Health, increasing it by nearly $2 to approximately $84 per share. They cite improved earnings visibility and strengthening fundamentals in the healthcare sector as key reasons for the change.Narrative-Update • Sep 04
Digital Health Transformation And Integrated Care Will Expand Reach
Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.Seeking Alpha • Mar 30
CVS Health: I Don't Understand The Fuss, But The Worst Is Behind
Summary CVS Health experienced a significant turnaround in 2025, with shares up nearly 50% after a 44% decline in 2024. The recent rally is not driven by great results or strong guidance under new CEO leadership, but rather bad ones that just weren't as terrible as expected. CVS's 2025 outlook includes modest revenue growth, improved operating income, and a focus on stabilizing margins and profitability. Despite uncertainties, CVS's valuation does seem fair considering the worst is seemingly behind, leading to an upgraded rating from 'Sell' to 'Hold'. Read the full article on Seeking AlphaSeeking Alpha • Feb 26
CVS Health: Incremental Improvement Best Hope For 2025 (Rating Downgrade)
Summary CVS Health experienced a significant share price decline in 2024, driven by earnings misses, CEO departure, and regulatory pressures on its PBM and Medicare Advantage businesses. Q4 2024 earnings showed revenue growth but declining operating income and EPS, with the healthcare benefits division facing rising costs and lower profitability. The new CEO aims to improve outcomes, increase access, and lower care costs, but faces challenges such as CMS rate negotiations and activist investor pressures. Despite recent share price gains, I downgrade CVS to "Hold" due to ongoing operational challenges and uncertainties about achieving a turnaround in 2025. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold
Summary Despite a >10% rise in CVS Health's stock price from my initial BUY recommendation, CVS Health is downgraded to Hold due to substantial political risks and declining cash flow. CVS faces significant challenges, including DOJ lawsuits, potential business separation, political scrutiny, and declining cash flow, impacting its turnaround prospects. CVS reported strong Q4 sales and new leadership from the new CEO David Joyner may bode well for shareholders. However, political risks and ongoing industry battles make CVS Health's turnaround uncertain, warranting a conservative Hold rating despite the recent rally in its stock price. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
CVS Health Isn't Going To The Dogs
Summary CVS Health's poor 2024 performance was driven by negative macro and micro factors. Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025. The company remains free cash flow positive, despite myriad challenges. I believe the cash dividend, now yielding 5 percent, remains safe. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
CVS Health: An Attractive 5.8% Safe Yield For Now
Summary Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share and pushing management to revise cash flow guidance down to $9.0 billion. The company saw double-digit revenue growth in two of its three segments, with a slight increase in pharmacy market share to 27.3%. With a potential upside of nearly 45%, CVS could be a compelling buy for patient investors, but I maintain a hold rating due to ongoing uncertainties. Read the full article on Seeking AlphaAktionärsrenditen
| CVS | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 1.5% | -0.4% | -0.3% |
| 1Y | 33.7% | 24.7% | 19.9% |
Rendite im Vergleich zur Industrie: CVS übertraf die Branche US Healthcare , die im vergangenen Jahr eine Rendite von 24.7 erzielte.
Rendite vs. Markt: CVS übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.9 erzielte.
Preisvolatilität
| CVS volatility | |
|---|---|
| CVS Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: CVS hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CVSDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1963 | 259,500 | J. Joyner | www.cvshealth.com |
Die CVS Health Corporation bietet Gesundheitslösungen in den Vereinigten Staaten an. Der Geschäftsbereich „Health Care Benefits“ umfasst traditionelle, freiwillige und verbraucherorientierte Krankenversicherungsprodukte sowie damit verbundene Dienstleistungen, darunter Kranken-, Apotheken-, Zahn- und psychologische Gesundheitspläne; medizinische Managementleistungen; Medicare-Advantage- und Medicare-Supplement-Pläne; Arzneimittelpläne (PDPs) sowie Medicaid-Gesundheitsmanagementdienste. Das Unternehmen betreut Arbeitgeberverbände, Einzelpersonen, Studierende, Teilzeit- und Stundenkräfte, Krankenkassen, Gesundheitsdienstleister, staatliche Stellen, staatlich geförderte Versicherungspläne, Gewerkschaften und im Ausland lebende Personen.
CVS Health Corporation's Grundlagenzusammenfassung
| CVS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$120.24b |
| Gewinn(TTM) | US$4.89b |
| Umsatz(TTM) | US$412.65b |
24.8x
Kurs-Gewinn-Verhältnis 0.3x
Kurs-Umsatz-VerhältnisIst CVS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CVS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$412.65b |
| Kosten der Einnahmen | US$356.34b |
| Bruttogewinn | US$56.31b |
| Sonstige Ausgaben | US$51.42b |
| Gewinn | US$4.89b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 3.82 |
| Bruttomarge | 13.64% |
| Nettogewinnspanne | 1.19% |
| Schulden/Eigenkapital-Verhältnis | 76.9% |
Wie hat sich CVS auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
2.8%
Aktuelle Dividendenrendite69%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/18 19:25 |
| Aktienkurs zum Tagesende | 2026/08/18 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CVS Health Corporation wird von 49 Analysten beobachtet. 22 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Harshit Gupta | Accountability Research Corporation |
| Christopher Graja | Argus Research Company |
| Hua Ha | Baird |